Author
The European Union is in the middle of revising its medicines legislation. This reform, often referred to as the “pharma package,” centers on a proposed new Pharmaceutical Regulation and a proposed new Pharmaceutical Directive. Its stated…
Before we can consider ways to address excessive pricing for orphan drugs, we must first diagnose the underlying problem.
By Timo Minssen, Esther van Zimmeren & Jakob Wested An earlier version of this contribution had been published in Life Science Intellectual Property Review (LSIPR). A voluntary pool or clearinghouse model may give rise to a robust commercial ecosystem…
By Jakob Wested, Timo Minssen & Esther van Zimmeren Another version of this contribution has been published in Life Science Intellectual Property Review (LSIPR). The Broad Institute is facing a formidable task in defending the revoked CRISPR patent…
